TMO vs WAT
TMO: Thermo Fisher Scientific is a leading global provider of mission-critical laboratory equipment, analytical instrumentation, and scientific services for research and clinical markets. WAT: A leading global analytical instruments and life sciences company combining chromatography, mass spectrometry, and diagnostic solutions following a transformative $16.8 billion acquisition of BD's biosciences and diagnostics businesses.
Side-by-side fundamentals
| Metric | TMO | WAT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $526.46 | $370.82 | |
| Market cap as of 2026-07-23 | $194.1B | $35.9B | |
| P/E as of 2026-07-23 | 28.36 | 79.82 | TMO lower |
| PEG as of 2026-07-23 | 2.89 | n/a | |
| Net margin as of 2026-07-23 | +15.2% | +11.9% | TMO higher |
| Gross margin as of 2026-07-23 | +40.9% | +55.1% | WAT higher |
| Operating margin as of 2026-07-23 | +17.5% | +16.0% | TMO higher |
| ROE as of 2026-07-23 | +13.2% | +8.0% | TMO higher |
| ROA as of 2026-07-23 | +6.4% | +4.6% | TMO higher |
| Debt / equity as of 2026-07-23 | 0.83 | 0.34 | WAT lower |
| Revenue growth (YoY) as of 2026-07-23 | +5.4% | +26.4% | WAT higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +2.1% | WAT higher |
| Dividend yield as of 2026-07-23 | +0.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.86 | 1.19 | |
| 1-year return as of 2026-07-22 close | +23.1% | +29.0% | WAT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.